Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2017, Article ID 6093695, 3 pages
https://doi.org/10.1155/2017/6093695
Case Report

A Case of Fulminant Meningococcemia: It Is All in the Complement

1Division of Infectious Disease, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
2Denver Health and Hospital Authority, Denver, CO, USA
3Division of Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA
4Division of Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA

Correspondence should be addressed to Kellie L. Hawkins; ude.revnedcu@snikwah.eillek

Received 5 April 2017; Revised 24 May 2017; Accepted 14 June 2017; Published 20 July 2017

Academic Editor: Alexandre Rodrigues Marra

Copyright © 2017 Kellie L. Hawkins et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Eculizumab is a novel monoclonal antibody that inhibits complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well-known risk factor for meningococcal infection. We describe a case of a young patient with PNH treated with eculizumab who presented with a life-threatening case of nongroupable meningococcemia. As this new biologic agent becomes more widely prescribed, providers should be aware of the increased risk of meningococcemia. In addition to vaccination, providers may consider the use of oral penicillin for antibiotic prophylaxis against Neisseria meningitidis in these cases of functional complement deficiency.